TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Allergy diagnosis:~  * A medical history of moderate to severe seasonal allergic rhinoconjunctivitis (SARC) for the grass pollen season during at least the two previous seasons (definition of allergy severity according to ARIA (Bousquet et al 2001))~ * A positive skin prick test (SPT - wheal diameter ≥ 3 mm) to grass pollen mixture, histamine wheal ≥ 3 mm, NaCl control reaction \< 2 mm~ * Specific IgE against grass pollen (with recombinant allergens - g213) \> 0.7 kU/L~ * Positive response to CPT with at least 10,000 SQ-E/mL of grass allergens~* Patients treated with anti-allergic medication for at least 2 grass pollen seasons prior to enrollment~* For asthmatic patients: confirmed diagnosis of controlled asthma according to Global Initiative for Asthma (GINA) guidelines (steps 1-3, GINA 2014)~Key Exclusion Criteria:~* Previous immunotherapy with grass allergens within the last 5 years~* Ongoing immunotherapy with grass allergens or any other allergens~* Patients with a history of anaphylaxis, including food (e.g. peanut or marine animals) or hymenoptera venom (e.g. bee or wasp stings) or medication (e.g. penicillin)~* Patients with partly controlled or uncontrolled asthma according to GINA guidelines (GINA 2014)~* Patients with chronic asthma or emphysema, particularly with a forced expiratory volume in 1 second (FEV1) \< 80% of the predicted value (ECSC) or with a peak expiratory flow (PEF) \< 70% of the individual optimum value~* Patients symptomatic to inhaled allergens circulating during the grass pollen season (specific to each country: e.g. birch, hazel, mugwort, ragweed, olive, Alternaria alternata)~* Patients symptomatic to perennial inhaled allergens (house dust mites, cat, dog) to which the patients are regularly exposed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- gpASIT+TM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, at least 18 years of age~* Has a total NIH-CPSI total score of 15~* Has a NIH-CPSI pain score of 8~* Has had pain in the pelvic region for at least 3 months prior to screening~Exclusion Criteria:~* Has previously participated in a Watson study with silodosin~* Has previously received α-blocked therapy for chronic prostatitis/chronic pelvic pain syndrome or is currently receiving α-blocked therapy for any condition~* Has experience ≥2 urinary tract infections within the previous 12 months~* Has any medical condition that in the opinion of the investigator precludes safe participation in the study~* Has any medical condition that could confound the efficacy evaluation~* Is receiving ketoconazole, or other known potent inhibitors of cytochrome P450 3A4 or any medication in the opinion of the investigator that precludes safe participation in the study~* Is receiving any medication that in the opinion of the investigator that could confound the efficacy evaluation~* Has participated in a study involving the administration of an investigational agent within the past 30 days

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silodosin 4 mg (Type: EXPERIMENTAL): 4 mg daily
- Silodosin 8 mg (Type: EXPERIMENTAL): Silodosin 8 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo capsule daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary Diagnosis of Major Depressive Disorder~* Hamilton Psychiatric Rating Scale for Depression-17-Item score of greater than or equal to 14 at baseline~Exclusion Criteria:~* Current psychoactive substance abuse or dependence, manic episode, or a lifetime diagnosis of bipolar or psychotic disorder~* Potentially violent to others or is at significant risk for suicide~* History or current evidence of gastrointestinal disease or history of surgery known to interfere with absorption or excretion~* Known presence of raised intraocular pressure or history of narrow angle glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine Succinate Sustained-Release Formulation 50 mg (Type: ACTIVE_COMPARATOR): None
- Desvenlafaxine Succinate Sustained-Release Formulation 25 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* GD patients will have been trated with methimazole and serum levels of TSH and FT4 should be in the normal range.~Exclusion Criteria:~* Pregnancy~* Allergy to antithyroid drugs (ATD)~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels more than two times the upper normal range~* Patients with coexistent endocrine or organ-specific autoimmune diseases (such as those with atopic dermatitis or bronchial asthma)~* Patients taking medications that could affect the immune system (such as corticosteroids), noncompliance because of psychiatric or other serious diseases~* Unwillingness to participate in the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Isotonic Na chloride (Type: EXPERIMENTAL): The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum urate level:~  * \>= 7.0mg/dL in patients with gouty nodule or with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL~* Disease type in the classification of hyperuricemia: Uric acid-underexcretion type or mixed type~* Outpatients~Exclusion Criteria:~* Gouty arthritis within 14 days before randomized allocation~* Secondary hyperuricemia~* HbA1c: \>= 8.4%~* Clinically significant cardiac, hepatic, renal, hematologic or endocrine disease~* Kidney calculi or clinically significant urinary calculi~* AST: \>= 100 IU/L or ALT: \>= 100 IU/L~* eGFR: \< 30 mL/min/1.73m\^2~* Systolic blood pressure: \>= 180 mmHg or diastolic blood pressure: \>= 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FYU-981 (Type: EXPERIMENTAL): None
- Febuxostat (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Food Additives Effects on EEG Profiles in College Students With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Generally good health~* 18-24 years old~* Currently attending college~* Physician's diagnosis of ADHD (unless control participant)~* Stable medication dose and frequency for 3 months before the study~* Willing to suspend ADHD medication administration on testing day and the day after testing~Exclusion Criteria:~* Presence of comorbid psychiatric condition other than comorbid depression or anxiety~* Autism~* Severe asthma requiring past hospitalization~* Seizure disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- ADHD- Artificial food coloring, then placebo (Type: EXPERIMENTAL): Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
- ADHD - Placebo, then artificial food coloring (Type: EXPERIMENTAL): Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
- Controls- Artificial food coloring, then placebo (Type: EXPERIMENTAL): Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
- Controls - Placebo, then artificial food coloring (Type: EXPERIMENTAL): Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* Non-dependent, recreational opioid users. (Must use opioid for non-therapeutic purposes on at least 10 occassions within the last year and at least once in the 8 weeks before Visit 1 (Screening Visit).~* Must have experience with intranasal opioid administration (snorted opioid drugs on at least 3 occassions within the last year before Visit 1 (Screening Visit).~Exclusion Criteria:~* Diagnosis of substance and/or alcohol dependence~* Subject has participated in, is currently participating in, or seeking treatment for substance and/or alcohol related disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: PLACEBO_COMPARATOR): None
- Treatment D (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Severe Childhood Aggression (The TOSCA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of ADHD, any subtype~* DSM-IV diagnosis of a disruptive behavior disorder, including CD or ODD~* Evidence of serious physical aggression, as rated on the Overt Aggression Scale-Modified, and as determined by parent or guardian ratings on the NCBRF D-Total Score. In addition, the blinded clinician must assign a clinical global impressions severity score of 4 or greater for aggression.~* Prior to random assignment, participants must be free of all psychotropic medicines for 2 weeks for most drugs (such as most antidepressants, alpha agonists, beta blockers, anxiolytics, mood stabilizers, and antihistamines), and 4 weeks for depot antipsychotics and fluoxetine.~Exclusion Criteria:~* Full-scale IQ below 71~* Pregnancy or a history of seizure disorder or other neurological or medical disorders for which medication may present a considerable risk~* Abnormal liver function~* Pervasive developmental disorder, schizophrenia or other psychotic disorders, or eating disorders~* Currently taking other psychotropic medications from which discontinuation would present a significant risk. Participants may not discontinue a satisfactory medication to participate.~* Presence or history of major depressive disorder~* Diagnosis of bipolar disorder~* A hypomanic/biphasic score of 36 or greater as rated by child's parent on the General Behavior Inventory and confirmed by clinician as indication of mood disorder~* Active substance abuse disorder or lack of control of substance use that does not allow for safe medication administration~* Evidence of current child abuse or neglect~* History of suicide attempt in the past year or current suicidal ideation with plan and/or intent~* Family history of type II diabetes in two or more first degree relatives, defined as biological parents and/or full biological siblings

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
- 2 (Type: ACTIVE_COMPARATOR): Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a clinical diagnosis of Huntington Disease (HD) with chorea~2. Be able to walk, with or without the assistance of a person or device~3. Participants of childbearing potential who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently while participating in the study until 30 days (females) or 90 days (males) after the last dose of the study drug~4. Be able to read and understand English~Exclusion Criteria:~1. Have a history of previously established therapy with a VMAT2 inhibitor, in the judgement of the investigator~2. Have difficulty swallowing~3. Are currently pregnant or breastfeeding~4. Have a known history of long QT syndrome, cardiac tachyarrhythmia, left bundle-branch block, atrioventricular block, uncontrolled bradyarrhythmia, or heart failure~5. Have an unstable or serious medical or psychiatric illness~6. Have a significant risk of suicidal behavior~7. Have a history of substance dependence or substance (drug) or alcohol abuse, within 1 year of screening~8. If taking antidepressant therapy, be on a stable regimen~9. Have received gene therapy at any time~10. Have received an investigational drug in a clinical study within 30 days of the baseline visit or plan to use such investigational drug (other than valbenazine) during the study~11. Have had a blood loss ≥550 milliliters (mL) or donated blood within 30 days before the baseline visit~12. Had a medically significant illness within 30 days before baseline, or any history of neuroleptic malignant syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Valbenazine (Type: EXPERIMENTAL): Capsule, administered orally once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Capsule, administered orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with previously untreated advanced stage, CD20-positive FL~* Patient with ECOG performance status 0, 1 or 2.~Exclusion Criteria:~* Patient with Grade 3b (aggressive) FL or any histology other than FL grade 1, 2 or 3a~* Patient who has previously received any prior therapy for lymphoma~* Patient with evidence of any uncontrolled, active infection (viral, bacterial or fungal).~* Patient with any malignancy within 5 years prior to date of randomization, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GP2013 (Type: EXPERIMENTAL): Type: Biological/Vaccine
- rituximab (Type: ACTIVE_COMPARATOR): Type: Biological/Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* macular edema associated with diabetes~* visual acuity between 20/50 and 20/200~Exclusion Criteria:~* recent laser therapy in the eye~* recent signs of uncontrolled diabetes~* blood pressure worse than 160/100~* severe cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham Control (Type: SHAM_COMPARATOR): None
- Macugen (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects aged between 16 and 25 as established by medical history and clinical examination~* Written informed consent will be obtained from each subject before the serum screening of HBV markers~* Seronegative for HBsAg, anti-HBs antibody, anti-HBc antibody~* Have never been immunized with HBV vaccine before~Exclusion Criteria:~* Subject has a medical history of allergic to any ingredient of vaccine~* Family history of seizures or progressive neurological disease~* Autoimmune disease or immunodeficiency~* Women with pregnant~* Bleeding disorder diagnosed by a doctor~* Chronic diseases: hepatitis, tumor, tuberculosis,et.al~* Any prior administration of immunoglobulins or blood products in the last 3 mon before recruitment~* Subjects had a medical history of serious adverse reactions to vaccines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- 20μg, 0-1-6 (Type: ACTIVE_COMPARATOR): 117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
- 60μg, 0-1 (Type: EXPERIMENTAL): 112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
- 60μg, 0-2 (Type: EXPERIMENTAL): 125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 10% Lidocaine Spray for Intrauterine Device Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman who required for Copper T IUD insertion~* Body mass index 18.5 - 30 kg/m2~* Communicable with Thai language~* New IUD user~Exclusion Criteria:~* Suspicion of pregnancy~* Puerperal sepsis/Immediate post-septic abortion~* Untreated abnormal uterine bleeding~* Uterine anomaly/abnormal pathology distorting the uterine cavity~* Current pelvic inflammatory disease~* Untreated cervicitis/vaginitis~* Wilson's disease~* Copper allergy~* known hypersensitivity to local anaesthetic~* Analgesic or anxiolytic use within the last 24 h before the procedure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- group A (Type: EXPERIMENTAL): 10% lidocaine spray
- group B (Type: PLACEBO_COMPARATOR): sterile water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete